Becker's Healthcare November 1, 2024
With high-cost specialty drugs making up an ever-greater percentage of new launches, and prices for existing brand biologics on an ongoing upward trajectory, biosimilars – lower cost alternatives to these expensive medications – brought with them the promise of lower costs for everyone. Yet, despite their potential, uptake has been slow and this promise has failed to materialize. Here’s a look at the top five challenges facing the biosimilars market today.
1. Complex Formulary Structures
Formulary management has become a significant obstacle to biosimilar adoption. When new biosimilars such as Amjevita™ were launched, their uptake was slow, not due to demand, but because of how they were positioned within formularies. The structure of these formularies often favors brand drugs driven...
Today's Sponsors
Today's Sponsor